🇺🇸 FDA
Pipeline program

SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets

20190172

Phase 3 small_molecule active

Quick answer

SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets for Colorectal Cancer (CRC) is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Colorectal Cancer (CRC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials